| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 173.93 | 21.2% |
| Total Income | 173.93 | 21.2% |
| Expenditure | 160.64 | 38.4% |
| PBT | 8.49 | 68.2% |
| Net Profit | 7.32 | 71.5% |
| OPM | 7.64% | 11.47pp |
| NPM | 4.21% | 13.69pp |
| EPS | 0.21 | 72.4% |
TransMedics Reports Q1 2026 Revenue $173.9 Million, Up 21% YoY
06 May 2026 · 6 May, 1:39 am
Summary
TransMedics Group, Inc. reported a 21% increase in total revenue for the first quarter of 2026, reaching $173.9 million compared to $143.5 million in the first quarter of 2025. Net income for the quarter was $7.3 million, or $0.20 per diluted share. The company is reiterating its full year 2026 revenue guidance to be in the range of $727 million to $757 million. TransMedics is focused on executing its multi-pronged growth strategy by accelerating ENHANCE heart and DENOVO lung programs in the U.S., launching its NOP model in Europe, and advancing its OCS Kidney program.
Key Highlights
- 1
TransMedics Group reported total revenue of $173.9 million in the first quarter of 2026, representing a 21% increase compared to the first quarter of 2025.
- 2
The company's net income for the first quarter of 2026 was $7.3 million, or $0.20 per fully diluted share.
- 3
Adjusted net income for the first quarter of 2026 reached $10.9 million, or $0.30 per fully diluted share.
- 4
TransMedics is reiterating its full year 2026 revenue guidance to be in the range of $727 million to $757 million.
- 5
The company owned 22 aircraft as of March 31, 2026.
- 6
TransMedics entered into a definitive agreement to invest in PAD Aviation to create the first dedicated European transplant logistic network.
Management Comments
Waleed Hassanein
MD
“We are pleased with our first quarter results and see 2026 as another critical period for TransMedics as we deliver on several critical growth catalysts for our business. We are laser focused on executing our multi-pronged growth strategy by accelerating ENHANCE heart and DENOVO lung programs in the U.S., launching our NOP model in Europe, and advancing our OCS Kidney program. We believe these initiatives will position us well to drive continued growth and expand access to life-saving transplants for patients globally.”
Informational and educational content only. Not investment advice.